Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005–2010

BMC Research Notes

Eduardo Rodriguez-Noriega³  Luis Petersen²  Esteban Gonzalez-Diaz³  Hector Raul Perez-Gomez³  Lorena Salcido-Gutierrez⁴  Helio S Sader¹  Juan Carlos Tinoco-Favila⁴  Rayo Morfin-Otero³ 

[1] JMI Laboratories, North Liberty, IA, USA;Instituto de Patología Infecciosa y Experimental, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Calle Hospital 308, Colonia El Retiro, CP 44280, Guadalajara, Jalisco, Mexico;Infectología, Microbiología, Hospital Civil de Guadalajara, Fray Antonio Alcalde, Guadalajara, Mexico;Laboratorio de Microbiología, Hospital General de Durango, Secretaria de Salud, Durango, Mexico

关键词: Infections;    Nosocomial;    Gram negative;    Resistance;    Bacterial;   

Others  :  1166353
DOI  :  10.1186/1756-0500-5-277

 received in 2012-01-13, accepted in 2012-06-07,  发布年份 2012

【 摘 要 】

Background

Hospital-acquired infections caused by multiresistant gram-negative bacteria are difficult to treat and cause high rates of morbidity and mortality. The analysis of antimicrobial resistance trends of gram-negative pathogens isolated from hospital-acquired infections is important for the development of antimicrobial stewardship programs. The information obtained from antimicrobial resistant programs from two hospitals from Mexico will be helpful in the selection of empiric therapy for hospital-acquired gram-negative infections.

Findings

Two thousand one hundred thirty two gram-negative bacteria collected between January 2005 and December 2010 from hospital-acquired infections occurring in two teaching hospitals in Mexico were evaluated. Escherichia coli was the most frequently isolated gram-negative bacteria, with >50% of strains resistant to ciprofloxacin and levofloxacin. Klebsiella spp. showed resistance rates similar to Escherichia coli for ceftazidime (33.1% vs 33.2%), but exhibited lower rates for levofloxacin (18.2% vs 56%). Of the samples collected for the third most common gram-negative bacteria, Pseudomonas aeruginosa, >12.8% were resistant to the carbapenems, imipenem and meropenem. The highest overall resistance was found in Acinetobacter spp. Enterobacter spp. showed high susceptibility to carbapenems.

Conclusions

E. coli was the most common nosocomial gram-negative bacilli isolated in this study and was found to have the second-highest resistance to fluoroquinolones (>57.9%, after Acinetobacter spp. 81.2%). This finding represents a disturbing development in a common nosocomial and community pathogen.

【 授权许可】

   
2012 Morfin-Otero et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK: NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect control hosp epidemiol 2008, 29(11):996-1011.
• [2]Peleg AY, Hooper DC: Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010, 362(19):1804-1813.
• [3]Kallen AJ, Hidron AI, Patel J, Srinivasan A: Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect Control Hosp Epidemiol 2010, 31(5):528-531.
• [4]Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, et al.: Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51(6):1987-1994.
• [5]Giske CG, Monnet DL, Cars O, Carmeli Y: Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008, 52(3):813-821.
• [6]Fridkin SK, Edwards JR, Tenover FC, Gaynes RP, McGowan JE: Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001, 33(3):324-330.
• [7]Pakyz AL: The utility of hospital antibiograms as tools for guiding empiric therapy and tracking resistance. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2007, 27(9):1306-1312.
• [8]El-Azizi M, Mushtaq A, Drake C, Lawhorn J, Barenfanger J, Verhulst S, Khardori N: Evaluating antibiograms to monitor drug resistance. Emerg Infect Dis 2005, 11(8):1301-1302.
• [9]Funke G, Funke-Kissling P: Evaluation of the new VITEK 2 card for identification of clinically relevant gram-negative rods. J Clin Microbiol 2004, 42(9):4067-4071.
• [10]Chatzigeorgiou KS, Sergentanis TN, Tsiodras S, Hamodrakas SJ, Bagos PG: Phoenix 100 versus Vitek 2 in the identification of gram-positive and gram-negative bacteria: a comprehensive meta-analysis. J Clin Microbiol 2011, 49(9):3284-3291.
• [11]CLSI: M07-A8: Methods for dilution antimicrobial susceptibility tests forbacteria that grow aerobically; approved standard. Wayne, PAClinical and Laboratory Standards Institute; 2009.
• [12]CLSI: M100S21: Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
• [13]Barry AL, Fuchs PC, Jones RN: Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents. Collaborative Antimicrobial Susceptibility Testing Group. Diagn Microbiol Infect Dis 1989, 12(5):413-420.
• [14]Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, Vatopoulos A, Gniadkowski M, Toth A, Pfeifer Y, et al.: Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010, 15(46):.
• [15]CLSI: M02-A11: Performance standards for antimicrobial disk susceptibility tests; approved standard-Eleventh edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
• [16]CLSI: Performance Standards for antimicrobial susceptibility testing: Twentieth informational supplement (June 2010 update). Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
• [17]MacGowan A: Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations. Clin Microbiol Infect 2008, 14(Suppl 1):166-168.
• [18]Garza-Gonzalez E, Mendoza Ibarra SI, Llaca-Diaz JM, Gonzalez GM: Molecular characterization and antimicrobial susceptibility of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae isolates at a tertiary-care centre in Monterrey, Mexico. J Med Microbiol 2011, 60(Pt 1):84-90.
• [19]Silva-Sanchez J, Garza-Ramos JU, Reyna-Flores F, Sanchez-Perez A, Rojas-Moreno T, Andrade-Almaraz V, Pastrana J, Castro-Romero JI, Vinuesa P, Barrios H, et al.: Extended-spectrum beta-lactamase-producing enterobacteriaceae causing nosocomial infections in Mexico. A retrospective and multicenter study. Archives Med Res 2011, 42(2):156-162.
• [20]Morfin-Otero R, Rodriguez-Noriega E, Deshpande LM, Sader HS, Castanheira M: Dissemination of a bla(VIM-2)-carrying integron among Enterobacteriaceae species in Mexico: report from the SENTRY Antimicrobial Surveillance Program. Microb Drug Resist 2009, 15(1):33-35.
• [21]Quinteros M, Radice M, Gardella N, Rodriguez MM, Costa N, Korbenfeld D, Couto E, Gutkind G: Extended-spectrum beta-lactamases in enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother 2003, 47(9):2864-2867.
• [22]Villegas MV, Correa A, Perez F, Miranda MC, Zuluaga T, Quinn JP: Prevalence and characterization of extended-spectrum beta-lactamases in Klebsiella pneumoniae and Escherichia coli isolates from Colombian hospitals. Diagn Microbiol Infect Dis 2004, 49(3):217-222.
• [23]Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN: Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Int J Antimicrob Agents 2005, 25(1):57-61.
• [24]Castanheira M, Sader HS, Jones RN: Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist 2010, 16(1):61-65.
• [25]Nordmann P, Cuzon G, Naas T: The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9(4):228-236.
• [26]Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW: Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010, 54(3):1160-1164.